Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/02/2010US20100303903 Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
12/02/2010US20100303902 Self-emulsifying pharmaceutical compositions of rhein or diacerein
12/02/2010US20100303900 Preparation of injectable suspensions having improved injectability
12/02/2010US20100303899 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
12/02/2010US20100303897 Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
12/02/2010US20100303896 5beta, 14beta-androstane derivatives useful for the treatment of restenosis after angioplastic or endoartherectomy and diseases due to organ fibrosis
12/02/2010US20100303895 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
12/02/2010US20100303892 Transdermal therapeutic system containing elongate hollow bodies
12/02/2010US20100303891 Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds
12/02/2010US20100303883 Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems
12/02/2010US20100303882 Medical Devices for Localized Drug Delivery
12/02/2010US20100303881 Therapeutic Electrospun Fiber Compositions
12/02/2010US20100303870 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
12/02/2010US20100303865 Use of oxazole derivatives for controlling fish parasites
12/02/2010US20100303851 Immunostimulation by chemically modified rna
12/02/2010US20100303840 Use of creatine or creatine analogs for the treatment of diseases of the nervous system
12/02/2010US20100303839 Methods and compositions for treatment of cancer using oncolytic rsv activity
12/02/2010US20100303838 Vectors for multiple gene expression
12/02/2010US20100303832 Genes and polymorphisms associated with amd
12/02/2010US20100303829 Hiv vpr-specific t cell receptors
12/02/2010US20100303825 Anti-estrogen and immune modulator combinations for treating breast cancer
12/02/2010US20100303822 Polypeptides from non-typeable haemophilus influenzae
12/02/2010US20100303820 Methods of treatment using il-17e antagonists
12/02/2010US20100303819 Dcl-1 and uses thereof
12/02/2010US20100303813 Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
12/02/2010US20100303812 Neutralizing monoclonal antibody against human dll4
12/02/2010US20100303809 Methods for the detection and quantitation of pten
12/02/2010US20100303803 Catenate for immunostimulation
12/02/2010US20100303799 Treatment of Conditions Related to Shock
12/02/2010US20100303790 Use of biliverdin reductase (bvr) and bvr peptide fragments to treat coronary disorders
12/02/2010US20100303785 Novel therapeutics based on tau/microtubule dynamics
12/02/2010US20100303784 Preparation for the prevention and/or treatment of vascular disorders
12/02/2010US20100303781 Treatment
12/02/2010US20100303776 Methods and compositions for regulated expression of multiple nucleic acids
12/02/2010US20100303760 Treatment and/or prevention of cancer and/or arthritis
12/02/2010US20100303758 Novel Glucocorticoid Receptor Agonists
12/02/2010US20100303755 Hepatitis C Virus Inhibitors
12/02/2010US20100303754 Process for preparation of cyclodextrin oligomers or polymers, products obtained and uses
12/02/2010US20100303753 Oligomer Conjugates of Lidocaine and Its Derivatives
12/02/2010US20100303744 Personal-care composition comprising oil-soluble solid sunscreens
12/02/2010US20100303740 Process for producing (3s)-i-menthyl 3-hydroxybutyrate and sensate composition
12/02/2010US20100303725 Technetium- and Rhenium-Bis(heteroaryl) Complexes, and Methods of Use Thereof
12/02/2010US20100303719 Anti-cancer compounds
12/02/2010US20100303718 Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials
12/02/2010US20100303717 Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials Cross Reference to Related Applications
12/02/2010US20100303716 Switchable nano-vehicle delivery systems, and methods for making and using them
12/02/2010US20100300438 Method and sedation delivery system including a pump assembly and a co-formulation of first and second drugs
12/02/2010DE102009022897A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022896A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022895A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022894A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022892A1 Substituierte Piperidine Substituted piperidines
12/02/2010DE102009022794A1 Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel Use of inhibitors of HAT and TMPRSS2 as drugs
12/02/2010DE102009022618A1 New hydropyrone derivatives useful as biocide, antibiotics, fungicide, antioomycetes, inhibitor for enzymes, disinfectant, textile modifier and wood preservative
12/02/2010DE102008033254B4 Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes A method for producing a pharmaceutical preparation for the oral therapy einphasischen the regulation of blood pressure
12/02/2010CA2772371A1 Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010CA2769769A1 Oxazolidinone containing dimer compounds, compositions and methods to make and use
12/02/2010CA2763939A1 Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
12/02/2010CA2763911A1 Azole antifungal compositions
12/02/2010CA2763851A1 New anthraquinone derivatives
12/02/2010CA2763700A1 2, 4-diamino pyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
12/02/2010CA2763633A1 Pyrimidine inhibitors of kinase activity
12/02/2010CA2763631A1 Pyrimidine inhibitors of kinase activity
12/02/2010CA2763624A1 Pyrimidine inhibitors of kinase activity
12/02/2010CA2763589A1 N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
12/02/2010CA2763572A1 Substituted aminopropionic derivatives as neprilysin inhibitors
12/02/2010CA2763565A1 Substituted aminobutyric derivatives as neprilysin inhibitors
12/02/2010CA2763541A1 Method for preparing hollow particles, and uses thereof
12/02/2010CA2763498A1 Pyrazinylpyrazoles
12/02/2010CA2763485A1 Methods for treating cancer and non-neoplastic conditions
12/02/2010CA2763472A1 Process for the production of benzofurans
12/02/2010CA2763471A1 Combination therapy for the treatment of multiple myeloma
12/02/2010CA2763465A1 A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
12/02/2010CA2763456A1 Reduction of flake-like aggregation in nanoparticulate active agent compositions
12/02/2010CA2763400A1 Substituted piperidines
12/02/2010CA2763386A1 Substituted piperidines
12/02/2010CA2763384A1 Use of a composition of a mixture of galactooligosaccharides for preventing diarrhoea
12/02/2010CA2763381A1 Substituted piperidines
12/02/2010CA2763365A1 Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
12/02/2010CA2763351A1 Substituted 3-(1,2,4-oxadiazol-5-yl)-5-phenylpiperidines
12/02/2010CA2763320A1 Oral medical composition and oral medical capsule enclosing the same
12/02/2010CA2763246A1 Ketolide compounds having antimicrobial activity
12/02/2010CA2763172A1 Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
12/02/2010CA2763140A1 Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
12/02/2010CA2763118A1 (dihydro) imidazoiso (5, 1-a)quinolines as fsh receptor agonists for the treatment of fertility disorders
12/02/2010CA2763041A1 Compositions and methods for modulating lipid composition
12/02/2010CA2763008A1 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
12/02/2010CA2762959A1 Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
12/02/2010CA2762917A1 Salts of methyl (r)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylate
12/02/2010CA2762885A1 Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
12/02/2010CA2762620A1 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors
12/02/2010CA2762582A1 Hiv protease inhibitors
12/02/2010CA2762528A1 Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder
12/02/2010CA2762479A1 Inhibitors of c-met protein kinase
12/02/2010CA2762474A1 Method of providing neuroprotection using substituted porphyrins
12/02/2010CA2762348A1 Stabilized and lyophilized formulation of anthracycline compounds
12/02/2010CA2762303A1 Differentiation therapy for sarcomas
12/02/2010CA2762190A1 Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
12/02/2010CA2762186A1 Substituted pyrazole inhibitors of c-met protein kinase
12/02/2010CA2762137A1 Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
1 ... 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 ... 7860